SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenomics, Inc., a Florida corporation, with a report date of July 8, 2005. The filing addresses corporate governance changes and executive appointments. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Consulting Compensation: $16,500 per month for Gabriele M. Cerrone.
- Contract Term: Three years with automatic one-year renewals.
Material Changes
The primary material change reported is the appointment of Gabriele M. Cerrone as a director and Co-Chairman of the Board of Directors, effective July 8, 2005. This appointment was formalized under a Closing Agreement dated July 2, 2004. Additionally, Mr. Cerrone entered into a new consulting agreement on June 27, 2005, outlining duties in business development, strategic planning, and capital markets.
Outlook, Risks, and Contingencies
The filing details specific contingencies regarding the termination of Mr. Cerrone's consulting agreement:
- Termination without Cause/Good Reason: Mr. Cerrone is entitled to a cash payment equal to the aggregate compensation for the remaining term of the agreement. All unvested stock options would immediately vest, with the exercise period extended to the later of the plan's maximum or ten years.
- Change of Control: Similar compensation and vesting protections apply if the agreement is terminated within two years of a change in control, excluding terminations due to death, disability, retirement, or cause.
Key Facts for Investor Verification
- Confirm the registrant identity is Xenomics, Inc., not Cardiff Oncology, Inc.
- Verify the terms of the Closing Agreement dated July 2, 2004, referenced in Exhibit 2.2.
- Assess the impact of the $16,500 monthly consulting fee and potential severance liabilities on the company's cash position.
- Review the vesting schedule and exercise terms of Mr. Cerrone's stock options.